CervoMed Inc.CRVOEarnings & Financial Report
CervoMed Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative conditions such as Alzheimer’s disease and other forms of dementia. It operates in the global biopharmaceutical market, with core R&D segments dedicated to addressing unmet medical needs for patients with progressive brain disorders.
CRVO Q2 FY2025 Key Financial Metrics
Revenue
$1.8M
Gross Profit
N/A
Operating Profit
$-6.6M
Net Profit
$-6.3M
Gross Margin
N/A
Operating Margin
-376.4%
Net Margin
-356.1%
YoY Growth
-46.6%
EPS
$-0.70
CervoMed Inc. Q2 FY2025 Financial Summary
CervoMed Inc. reported revenue of $1.8M (down 46.6% YoY) for Q2 FY2025, with a net profit of $-6.3M (down 170.1% YoY) (-356.1% margin).
Key Financial Metrics
| Total Revenue | $1.8M |
|---|---|
| Net Profit | $-6.3M |
| Gross Margin | N/A |
| Operating Margin | -376.4% |
| Report Period | Q2 FY2025 |
CervoMed Inc. Annual Revenue by Year
CervoMed Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $9.7M).
CervoMed Inc. Quarterly Revenue & Net Profit History
CervoMed Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $1.8M | -46.6% | $-6.3M | -356.1% |
| Q1 FY2025 | $1.9M | -18.3% | $-4.9M | -255.2% |
| Q4 FY2024 | $2.2M | -13.2% | $-6.7M | -310.2% |
| Q3 FY2024 | $1.9M | +27.1% | $-4.8M | -245.1% |
| Q2 FY2024 | $3.3M | +91.2% | $-2.3M | -70.4% |
| Q1 FY2024 | $2.3M | +66.7% | $-2.5M | -107.1% |
| Q4 FY2023 | $2.5M | — | $-2.4M | -94.9% |
| Q3 FY2023 | $1.5M | — | $2.2M | 140.9% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $2.5M | $2.3M | $3.3M | $1.9M | $2.2M | $1.9M | $1.8M |
| YoY Growth | N/A | N/A | 66.7% | 91.2% | 27.1% | -13.2% | -18.3% | -46.6% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $12.0M | $10.0M | $8.0M | $53.2M | $48.9M | $43.1M | $38.6M | $38.1M |
| Liabilities | $2.5M | $2.6M | $2.7M | $3.2M | $3.2M | $3.9M | $3.9M | $4.6M |
| Equity | $9.6M | $7.4M | $5.3M | $50.0M | $45.6M | $39.2M | $34.6M | $33.4M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.5M | $-2.5M | $-1.4M | $-2.2M | $-4.9M | $-8.1M | $-3.9M | $-6.5M |